Unexpected Intraoperative Events of Sustained Release-corticosteroid Implant When Used in the Context of Pars Plana Vitrectomy Surgery


Intravitreal dexamethasone implant (Ozurdex) and fluocinolone acetonide implant (Iluvien®) are FDA approved sustained-release corticosteroid treatments for use in macular edema secondary to diabetic retinopathy. The benefits of Ozurdex implants are also extended to the treatment of retinal vein occlusion-related macular edema and noninfectious uveitis of the posterior segment. In contrast to several other medications, the half-life of the Iluvien and Ozurdex implants h as not shown to be significantly affected by vitrectomy making them viable treatment options for vitrectomized eyes. In this report, we wish to raise awareness of a several unexpected intraoperative adverse events encountered during combined PPV and sustained-release corticosteroid implant surgery.



Ahmed Sallam
Little Rock, United States
Email : ahmedsallam11@yahoo.com
Cell Phone: +15013982074
Work Phone: +15016825000